.jpg)
.png)
Top Stories
On January 29, the U.S. FDA approved mipomersen sodium injection as an adjunct to treat LDL-C, Apo B, total cholesterol, and non HDL-C in patients with homozygous familial hypercholesterolemia (HoFH). Mipomersen, known by the brand name Kynamro, will be marketed in the U.S. by Genzyme, a Sanofi... more
The National Lipid Association's (NLA) Annual Summary of Clinical Lipidology 2016 was just published the Journal of Clinical Lipidology. This year's summary enhances the NLA's established commitment to a patient-centered approach and individualized care, which is an approach now... more
On April 23, Amarin Corp. issued a press release announcing that the U.S. FDA has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high... more
The new ICD-10 Codes were released by the Center for Medicare & Medicaid Services (CMS). Two new specific codes for FH have been approved: E78.01: Familial hypercholesterolemia Z83.42: Family history of familial hypercholesterolemia The National Lipid Association (NLA) in... more
Patient-centered recommendations for people needing additional cholesterol reduction Download the NLA PCSK9 Update Infographic PHILADELPHIA — The National Lipid Association (NLA) assembled a panel of experts to update its guidance for the use of PCSK9 antibody therapy made in the... more
James A. Underberg, MD, MS, Elected President during the 2017 NLA Scientific Sessions in Philadelphia PHILADELPHIA, Pa. — The National Lipid Association (NLA) announced the election of new President James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA, on Saturday at the 2017 Scientific Sessions... more
The National Lipid Association along with a panel of outside experts from various disciplines convened for a workshop in late July to examine how health information technology (HIT) can be used, to effectively improve LDL-C goal attainment. The workshop committee of experts included participants... more
2014 NLA Honors & Awards To honor the exceptional professionals in our ranks, the NLA has established several types of recognition. We are currently seeking nominations for the following awards, to be presented at the 2014 Annual Scientific Sessions in Orlando, Florida (May 1-4, 2014):... more
The Journal of Clinical Lipidology announced on Monday its 2016 Impact Factor has risen to 5.812, up from 4.906 in 2015. Led by Editor-In-Chief W. Virgil Brown, M.D., the JCL has seen a steady growth in submissions and readership since first publishing in 2007. It now ranks 17th of 256 journals in... more
On February 28, 2012, the Food and Drug Administration (FDA) approved crucial changes to the safety label for statins. The changes are based upon the FDA's further review of the data and are as follows: Removing the recommendation for periodic monitoring of liver enzymes; Adding a warning... more